HOME >> MEDICINE >> NEWS
GL701 (prasterone) significantly reduces lupus flares

Philadelphia, Pa. - Oct. 31, 2000 - The incidence of debilitating flares or exacerbations that systemic lupus erythematosus (SLE or lupus) patients experience, some resulting in hospitalization, significantly declined with the use of GL701, according to a Phase III placebo-controlled, double-blind multicenter study conducted in Taiwan and presented at the 64th Annual Scientific Meeting of the American College of Rheumatology in Philadelphia. The drug used in this study is similar to Genelabs Technologies, Inc. (Nasdaq:GNLB) formulation of its investigational drug GL701. The study reported here today was conducted by Genelabs Biotechnology Co., Ltd. of Taiwan, a licensee of Genelabs Technologies, Inc.

"GL701 significantly reduced the percent of patients with flares. Since flares can punctuate the remission periods that lupus patients experience, the potential for this investigational drug to increase the duration of remission and decrease the number of flares that require hospitalization is an important therapeutic advance," says Deh-Ming Chang, M.D., coauthor of the study and Professor and Director of Rheumatology/Immunology at the Tri-Service General Hospital, Taipei, Taiwan, R.O.C.

In the study, Chang and his colleagues compared GL701 to placebo among 119 Taiwanese women with lupus. Patients were evaluated in a randomized double-blind comparison of GL701, 200 mg or placebo daily for 24 weeks. Investigators evaluated efficacy based on change in Systemic Lupus Activity Measure (SLAM) and change in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), which measure disease activity; physician and patient visual analog scales (VAS), which measure quality of life parameters; and percent of patients with definite flares.

Study results show that 18 percent of patients receiving GL701 experienced flares, compared to 34 percent of patients on placebo, a 46 percent reduction, which was significant (p=0.04). Moreover, no GL701 pa
'"/>

Contact: Beth Kaplan
212-601-8443
Porter Novelli
30-Oct-2000


Page: 1 2 3

Related medicine news :

1. Moving admitted ER patients into inpatient beds faster could significantly increase hospital revenue
2. Gastrointestinal disorders are associated significantly with sleepless nights
3. Landmark survey reveals asthma in children remains significantly out of control in the United States
4. Data suggest ADDERALL XR significantly improved simulated driving in young adults with ADHD
5. Elderly cancer patients are significantly under-represented in cancer clinical trials
6. Generic anti-inflammatory causes significantly fewer GI complications than branded medications
7. Study shows weight-based REBETOL dosing in combination with PEG-INTRON significantly improves ...
8. Radiotherapy + cetuximab significantly improve disease control and survival in head and neck cancer
9. New data show SPIRIVA significantly reduces COPD exacerbations and related health resource burden
10. GSKS Requip(R) (ropinirole HCl) significantly reduces periodic leg movements in patients with RLS
11. Two landmark studies show Taxotere (R) significantly improves survival in men with prostate cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: prasterone significantly reduces lupus flares

(Date:11/26/2014)... (PRWEB) November 26, 2014 The ... submissions for the tenth annual MEDA Awards, which, ... development excellence in Maryland. “The MEDA Awards recognize ... prosperity to the state. We encourage our members ... are making a positive economic impact in the ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Increasing ... which include image guided surgeries has paved way ... injectors. Rising incidence of various types of cancers ... proportionate increase in demand for these owing to ... of contrast media injectors market can also be ...
(Date:11/26/2014)... German scientists say carbon-based synthetic molecules ... mesothelioma that looks and acts similar to asbestos-induced mesothelioma. ... the research. Click here to read it now. ... and Experimental Medicine in Hannover injected 500 lab rats ... rats eventually developed mesothelioma , how quickly it ...
(Date:11/26/2014)... November 26, 2014 For its ... published The AIS Report on Blue Cross and Blue ... Inc. on the varied strategies the two Blues plans ... compliance with treatments for sleep apnea, ranging from brick-and-mortar ... because it’s linked to increased rates of a variety ...
(Date:11/26/2014)... 26, 2014 With Thousand Oaks cosmetic ... the prosthodontists at the Anacapa Dental Art Institute in Woodland ... can be daunting for some. , That is why they ... they offer. , “No dentist wants cost to come between ... teeth,” said Dr. Mamaly Reshad, partner in the Anacapa Dental ...
Breaking Medicine News(10 mins):Health News:Maryland Economic Development Association Seeking Submissions for 2015 Awards 2Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 2Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 2Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 3Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 4Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 5
(Date:11/24/2014)... - Milestone Pharmaceuticals, Inc. today announced data from a Phase ... Australia of MSP-2017, a novel calcium ... supraventricular tachycardia (PSVT).  The results demonstrated that an ... single doses up to and including 140 mg ... including rapid onset, and validating proof of concept ...
(Date:11/24/2014)... Fla. , Nov. 24, 2014  Marta Rendon, MD, ... Boca Raton , FL and international key opinion ... selected from the United States to ... Istanbul, Turkey . Here, at this gathering ... West, as world renowned facial plastic surgery experts from ...
(Date:11/24/2014)... The Female Health Company (NASDAQ-CM: FHCO), today announced that ... its operating results for the fourth quarter and fiscal ... 2014 at 11:00 a.m. Eastern Standard Time (EST).  The ... same day. Shareholders and other interested parties ... (international participants dial 1-412-317-6716) and asking to be connected ...
Breaking Medicine Technology:Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 2Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 3Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 2Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 3The Female Health Company To Report FY2014 Operating Results on Tuesday, December 2, 2014 2
Cached News: